• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Clinical experience with multiagent intravesical therapy in interstitial cystitis patients unresponsive to single-agent therapy.

作者信息

Ghoniem G M, McBride D, Sood O P, Lewis V

机构信息

Department of Urology, Tulane University School of Medicine, New Orleans, LA 70112.

出版信息

World J Urol. 1993;11(3):178-82. doi: 10.1007/BF00211416.

DOI:10.1007/BF00211416
PMID:8401639
Abstract

A total of 25 patients with the diagnosis of interstitial cystitis (IC) were involved in this study. All patients had been previously diagnosed with interstitial cystitis and had received treatment with single intravesical agents. Patients were divided into two groups according to their bladder capacity. The bladder capacity was > 350 ml in group I patients and < 350 ml in group II patients. For our study, dimethylsulfoxide (DMSO), methylprednisolone, and heparin sulfate were given every week for a total of 6 weeks. When symptoms recurred, supportive oral pharmacotherapy consisting of anticholinergics and/or tricyclic antidepressants was given. Under anesthesia, patients in group I showed a 99% increase in their bladder capacity; whereas those in group II showed an increase of only 19%. Cystoscopically, Hunner's ulcers were present in 60% of the group II patients but were seen in only 5% of the group I patients. Histopathological examination showed that the inflammatory changes were more frequent and severe in group II than in group I. Mast-cell hyperplasia was present in 100% of the patients in group II, versus only 61% of those in group I. A total of 23 patients (92%) achieved an initial remission averaging 8.1 months. In all, 9 patients (35%) had 1 or more relapses, and all achieved a subsequent remission averaging 8 months. By this combined multiagent approach, the majority of patients with IC obtained relief from their incapacitating symptoms and were socially rehabilitated.

摘要

相似文献

1
Clinical experience with multiagent intravesical therapy in interstitial cystitis patients unresponsive to single-agent therapy.
World J Urol. 1993;11(3):178-82. doi: 10.1007/BF00211416.
2
Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome.膀胱内注射二甲亚砜/肝素/氢化可的松治疗间质性膀胱炎/膀胱疼痛综合征的长期疗效
Int Urogynecol J. 2017 Jul;28(7):1085-1089. doi: 10.1007/s00192-016-3232-0. Epub 2016 Dec 16.
3
Interstitial cystitis: urgency and frequency syndrome.间质性膀胱炎:尿急尿频综合征。
Am Fam Physician. 2001 Oct 1;64(7):1199-206.
4
Prolongation of response to DMSO by heparin maintenance.通过肝素维持延长对二甲基亚砜的反应
Urology. 1993 Jan;41(1 Suppl):64-6. doi: 10.1016/0090-4295(93)90198-j.
5
Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review.二甲基亚砜(DMSO)作为间质性膀胱炎/膀胱疼痛综合征的膀胱内治疗:综述。
Neurourol Urodyn. 2017 Sep;36(7):1677-1684. doi: 10.1002/nau.23204. Epub 2017 Feb 21.
6
Interstitial cystitis/painful bladder syndrome.间质性膀胱炎/膀胱疼痛综合征。
Am Fam Physician. 2011 May 15;83(10):1175-81.
7
Intravesical 50% dimethyl sulfoxide (Rimso-50) in treatment of interstitial cystitis.
Urology. 1987 Apr;29(4 Suppl):17-21.
8
Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC).膀胱疼痛综合征(BPS)/间质性膀胱炎(IC)膀胱内治疗的进展
Low Urin Tract Symptoms. 2018 Jan;10(1):3-11. doi: 10.1111/luts.12214.
9
Further experience with intravesical dimethyl sulfoxide in the treatment of interstitial cystitis.
J Urol. 1976 Jul;116(1):36-8. doi: 10.1016/s0022-5347(17)58662-0.
10
Prospective study of intravesical dimethyl sulphoxide in the treatment of chronic inflammatory bladder disease.
Br J Urol. 1987 Feb;59(2):142-4. doi: 10.1111/j.1464-410x.1987.tb04805.x.

引用本文的文献

1
General Overview of Artificial Intelligence for Interstitial Cystitis in Urology.泌尿外科间质性膀胱炎人工智能概述
Int Neurourol J. 2023 Nov;27(Suppl 2):S64-72. doi: 10.5213/inj.2346294.147. Epub 2023 Nov 30.
2
Intravesical Bladder Treatment and Deep Learning Applications to Improve Irritative Voiding Symptoms Caused by Interstitial Cystitis: A Literature Review.膀胱内膀胱治疗及深度学习应用改善间质性膀胱炎引起的刺激性排尿症状:文献综述
Int Neurourol J. 2023 May;27(Suppl 1):S13-20. doi: 10.5213/inj.2346106.053. Epub 2023 May 31.
3
Biofilm Formation by Uropathogenic Escherichia coli Is Favored under Oxygen Conditions That Mimic the Bladder Environment.

本文引用的文献

1
An abnormal leukocyte response in interstitial cystitis.间质性膀胱炎中的异常白细胞反应。
J Urol. 1962 Sep;88:387-91. doi: 10.1016/S0022-5347(17)64806-7.
2
On the use of an antihistamine in the treatment of interstitial cystitis.关于使用抗组胺药治疗间质性膀胱炎
Am Surg. 1958 Sep;24(9):664-7.
3
Prospective study of intravesical dimethyl sulfoxide in treatment of suspected early interstitial cystitis.膀胱内注射二甲基亚砜治疗疑似早期间质性膀胱炎的前瞻性研究。
尿路致病性大肠杆菌的生物膜形成在模拟膀胱环境的含氧条件下更为有利。
Int J Mol Sci. 2017 Sep 30;18(10):2077. doi: 10.3390/ijms18102077.
4
Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome.膀胱内注射二甲亚砜/肝素/氢化可的松治疗间质性膀胱炎/膀胱疼痛综合征的长期疗效
Int Urogynecol J. 2017 Jul;28(7):1085-1089. doi: 10.1007/s00192-016-3232-0. Epub 2016 Dec 16.
5
CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome.加拿大泌尿外科学会指南:间质性膀胱炎/膀胱疼痛综合征的诊断与治疗
Can Urol Assoc J. 2016 May-Jun;10(5-6):E136-E155. doi: 10.5489/cuaj.3786. Epub 2016 May 12.
6
Advances in intravesical therapy for urinary tract disorders.用于治疗尿路疾病的膀胱内治疗进展。
Expert Opin Drug Deliv. 2016;13(1):71-84. doi: 10.1517/17425247.2016.1100166. Epub 2015 Oct 19.
7
Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome.目前关于间质性膀胱炎/膀胱疼痛综合征膀胱灌注治疗的推荐。
Curr Urol Rep. 2013 Oct;14(5):442-7. doi: 10.1007/s11934-013-0369-y.
8
Intravesical treatments of bladder pain syndrome/interstitial cystitis.膀胱疼痛综合征/间质性膀胱炎的膀胱内治疗。
Nat Rev Urol. 2012 Dec;9(12):707-20. doi: 10.1038/nrurol.2012.217. Epub 2012 Nov 27.
9
Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail.影响使用二甲基亚砜混合液膀胱内灌注疗法治疗间质性膀胱炎的危险因素。
Int Urogynecol J. 2012 Nov;23(11):1533-9. doi: 10.1007/s00192-012-1699-x. Epub 2012 Mar 17.
10
Intravesical dimethyl sulfoxide inhibits acute and chronic bladder inflammation in transgenic experimental autoimmune cystitis models.膀胱内注射二甲基亚砜可抑制转基因实验性自身免疫性膀胱炎模型中的急性和慢性膀胱炎症。
J Biomed Biotechnol. 2011;2011:937061. doi: 10.1155/2011/937061. Epub 2010 Nov 11.
Urology. 1981 Jul;18(1):21-6. doi: 10.1016/0090-4295(81)90489-1.
4
Amitriptyline and perphenazine (Triptafen DA) in chronic pain.阿米替林与奋乃静(复方阿米替林)治疗慢性疼痛
Anaesthesia. 1981 Feb;36(2):210-2. doi: 10.1111/j.1365-2044.1981.tb08728.x.
5
Inflammatory plasma cell infiltration of the urinary bladder in the aging C57BL/Icrfa(t) mouse.衰老的C57BL/Icrfa(t)小鼠膀胱中的炎性浆细胞浸润。
Invest Urol. 1981 Sep;19(2):75-8.
6
Mast cells in interstitial cystitis.间质性膀胱炎中的肥大细胞。
Br J Urol. 1982 Jun;54(3):283-6. doi: 10.1111/j.1464-410x.1982.tb06976.x.
7
Vascular immunopathology in interstitial cystitis.间质性膀胱炎中的血管免疫病理学
Clin Immunol Immunopathol. 1982 Jun;23(3):648-55. doi: 10.1016/0090-1229(82)90327-0.
8
Chronic interstitial cystitis: increased levels of eosinophil cationic protein in serum and urine and an ameliorating effect of subcutaneous heparin.慢性间质性膀胱炎:血清和尿液中嗜酸性粒细胞阳离子蛋白水平升高以及皮下注射肝素的改善作用。
Scand J Urol Nephrol. 1983;17(2):159-61. doi: 10.3109/00365598309180161.
9
Serum immunoglobulin and complement alterations in interstitial cystitis.间质性膀胱炎患者血清免疫球蛋白及补体的变化
Eur Urol. 1983;9(6):350-2. doi: 10.1159/000474122.
10
Sigmoidocystoplasty to augment bladder capacity.乙状结肠膀胱扩大术以增加膀胱容量。
Surg Gynecol Obstet. 1984 Oct;159(4):377-80.